{"POml2n8AAAAJ": [["Jane A Foster", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["Sidney H Kennedy", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["Volodymyr Yerko", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["Victoria S Marshe", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["Gustavo Turecki", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["Charles F Reynolds III", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["Jordan F Karp", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["James L Kennedy", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["Jennie Yang", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["Daniel J M\u00fcller", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["Farhana Islam", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["Daniel M Blumberger", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["Benoit H Mulsant", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["Eric J Lenze", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["Laura M Fiori", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["Malgorzata Maciukiewicz", 2020, "Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine"], ["Jacqueline K Harris", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["CAN-BIND Investigator Team", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["Glenda MacQueen", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["Stefanie Hassel", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["Stephen C Strother", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["Roumen Milev", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["Gulshan B Sharma", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["Jonathan Downar", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["Andrew D Davis", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["Mojdeh Zamyadi", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["Arun Ravindran", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["G\u00e9sine L Alders", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["Geoffrey B Hall", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["Luciano Minuzzi", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["Raymond W Lam", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["Benicio N Frey", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["Stephen R Arnott", 2020, "Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study"], ["Peter Fettes", 2020, "Dorsomedial prefrontal cortex repetitive transcranial magnetic stimulation for treatment-refractory major depressive disorder: A three-arm, blinded, randomized controlled trial"], ["Zafiris J Daskalakis", 2020, "Dorsomedial prefrontal cortex repetitive transcranial magnetic stimulation for treatment-refractory major depressive disorder: A three-arm, blinded, randomized controlled trial"], ["Jack Sheen", 2020, "Dorsomedial prefrontal cortex repetitive transcranial magnetic stimulation for treatment-refractory major depressive disorder: A three-arm, blinded, randomized controlled trial"], ["Katharine Dunlop", 2020, "Dorsomedial prefrontal cortex repetitive transcranial magnetic stimulation for treatment-refractory major depressive disorder: A three-arm, blinded, randomized controlled trial"], ["Kfir Feffer", 2020, "Dorsomedial prefrontal cortex repetitive transcranial magnetic stimulation for treatment-refractory major depressive disorder: A three-arm, blinded, randomized controlled trial"], ["Laura Schulze", 2020, "Dorsomedial prefrontal cortex repetitive transcranial magnetic stimulation for treatment-refractory major depressive disorder: A three-arm, blinded, randomized controlled trial"], ["Peter Giacobbe", 2020, "Dorsomedial prefrontal cortex repetitive transcranial magnetic stimulation for treatment-refractory major depressive disorder: A three-arm, blinded, randomized controlled trial"], ["Farrokh Mansouri", 2020, "Dorsomedial prefrontal cortex repetitive transcranial magnetic stimulation for treatment-refractory major depressive disorder: A three-arm, blinded, randomized controlled trial"], ["Blake Woodside", 2020, "Dorsomedial prefrontal cortex repetitive transcranial magnetic stimulation for treatment-refractory major depressive disorder: A three-arm, blinded, randomized controlled trial"], ["Signe L Bray", 2020, "Aberrant limbic brain structures in young individuals at risk for mental illness"], ["Meghan Muller", 2020, "Aberrant limbic brain structures in young individuals at risk for mental illness"], ["Glenda M MacQueen", 2020, "Aberrant limbic brain structures in young individuals at risk for mental illness"], ["Catherine Lebel", 2020, "Aberrant limbic brain structures in young individuals at risk for mental illness"], ["Benjamin I Goldstein", 2020, "Aberrant limbic brain structures in young individuals at risk for mental illness"], ["Paul D Metzak", 2020, "Aberrant limbic brain structures in young individuals at risk for mental illness"], ["Amelia Srajer", 2020, "Aberrant limbic brain structures in young individuals at risk for mental illness"], ["Zahinoor Ismail", 2020, "Aberrant limbic brain structures in young individuals at risk for mental illness"], ["Nikita Nogovitsyn", 2020, "Aberrant limbic brain structures in young individuals at risk for mental illness"], ["JianLi Wang", 2020, "Aberrant limbic brain structures in young individuals at risk for mental illness"], ["Andrea Protzner", 2020, "Aberrant limbic brain structures in young individuals at risk for mental illness"], ["Bradley J MacIntosh", 2020, "Aberrant limbic brain structures in young individuals at risk for mental illness"], ["Jean Addington", 2020, "Aberrant limbic brain structures in young individuals at risk for mental illness"], ["Roberto Souza", 2020, "Aberrant limbic brain structures in young individuals at risk for mental illness"], ["Andrew Davis", 2020, "An investigation of cortical thickness and antidepressant response in major depressive disorder: a CAN-BIND study report"], ["Jacqueline Harris", 2020, "An investigation of cortical thickness and antidepressant response in major depressive disorder: a CAN-BIND study report"], ["Roberto B Sassi", 2020, "An investigation of cortical thickness and antidepressant response in major depressive disorder: a CAN-BIND study report"], ["Pradeep Reddy Raamana", 2020, "An investigation of cortical thickness and antidepressant response in major depressive disorder: a CAN-BIND study report"], ["Jee Su Suh", 2020, "An investigation of cortical thickness and antidepressant response in major depressive disorder: a CAN-BIND study report"], ["Olga Santesteban\u2010Echarri", 2020, "Personality and risk for serious mental illness"], ["Signe Bray", 2020, "Personality and risk for serious mental illness"], ["Mary Pat McAndrews", 2020, "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression"], ["Claudio N Soares", 2020, "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression"], ["Colleen A Brenner", 2020, "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression"], ["Yasaman Vaghei", 2020, "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression"], ["Sravya Atluri", 2020, "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression"], ["Willy Wong", 2020, "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression"], ["Rudolf Uher", 2020, "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression"], ["Daniel J Mueller", 2020, "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression"], ["Esther Alonso-Prieto", 2020, "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression"], ["Sagar V Parikh", 2020, "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression"], ["Killian Kleffner", 2020, "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression"], ["Fidel Vila-Rodriguez", 2020, "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression"], ["Andrey Zhdanov", 2020, "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression"], ["Faranak Farzan", 2020, "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression"], ["Susan Rotzinger", 2020, "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression"], ["Jacqueline Stowkowy", 2020, "Trauma in youth at-risk for serious mental illness"], ["Jianli Wang", 2020, "Trauma in youth at-risk for serious mental illness"], ["Jean M Addington", 2020, "Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report"], ["Kate L Harkness", 2020, "Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report"], ["Clement Hamani", 2020, "Neuroanatomical predictors of response to subcallosal cingulate deep brain stimulation for treatment-resistant depression"], ["Natasha Jawa", 2020, "Neuroanatomical predictors of response to subcallosal cingulate deep brain stimulation for treatment-resistant depression"], ["Sakina J Rizvi", 2020, "Neuroanatomical predictors of response to subcallosal cingulate deep brain stimulation for treatment-resistant depression"], ["Helen S Mayberg", 2020, "Neuroanatomical predictors of response to subcallosal cingulate deep brain stimulation for treatment-resistant depression"], ["M Mallar Chakravarty", 2020, "Neuroanatomical predictors of response to subcallosal cingulate deep brain stimulation for treatment-resistant depression"], ["Tejas Sankar", 2020, "Neuroanatomical predictors of response to subcallosal cingulate deep brain stimulation for treatment-resistant depression"], ["Stanley X Li", 2020, "Neuroanatomical predictors of response to subcallosal cingulate deep brain stimulation for treatment-resistant depression"], ["Andres M Lozano", 2020, "Neuroanatomical predictors of response to subcallosal cingulate deep brain stimulation for treatment-resistant depression"], ["Antoine Yrondi", 2019, "Association between side effects and blood microRNA expression levels and their targeted pathways in patients with major depressive disorder treated by a selective serotonin \u2026"], ["Sidney Kennedy", 2019, "The Anhedonia Trifecta: Clinical, Neuroimaging and Molecular Associations of Anhedonia and Antidepressant Response"], ["D Baliunas", 2019, "Predisposing and protective factors influencing suicide ideation, attempt, and death in patients accessing substance use treatment: a systematic review and meta-analysis protocol"], ["L Quilty", 2019, "Predisposing and protective factors influencing suicide ideation, attempt, and death in patients accessing substance use treatment: a systematic review and meta-analysis protocol"], ["V De Luca", 2019, "Predisposing and protective factors influencing suicide ideation, attempt, and death in patients accessing substance use treatment: a systematic review and meta-analysis protocol"], ["SJ Rizvi", 2019, "Predisposing and protective factors influencing suicide ideation, attempt, and death in patients accessing substance use treatment: a systematic review and meta-analysis protocol"], ["S Espinet", 2019, "Predisposing and protective factors influencing suicide ideation, attempt, and death in patients accessing substance use treatment: a systematic review and meta-analysis protocol"], ["S Kennedy", 2019, "Predisposing and protective factors influencing suicide ideation, attempt, and death in patients accessing substance use treatment: a systematic review and meta-analysis protocol"], ["P Selby", 2019, "Predisposing and protective factors influencing suicide ideation, attempt, and death in patients accessing substance use treatment: a systematic review and meta-analysis protocol"], ["T Corrin", 2019, "Predisposing and protective factors influencing suicide ideation, attempt, and death in patients accessing substance use treatment: a systematic review and meta-analysis protocol"], ["L Zawertailo", 2019, "Predisposing and protective factors influencing suicide ideation, attempt, and death in patients accessing substance use treatment: a systematic review and meta-analysis protocol"], ["W deRuiter", 2019, "Predisposing and protective factors influencing suicide ideation, attempt, and death in patients accessing substance use treatment: a systematic review and meta-analysis protocol"], ["S Bonato", 2019, "Predisposing and protective factors influencing suicide ideation, attempt, and death in patients accessing substance use treatment: a systematic review and meta-analysis protocol"], ["Lu Liu", 2019, "Clinical staging for youth at\u2010risk for serious mental illness"], ["Thomas Lapointe", 2019, "Reverse Translation of Major Depressive Disorder Symptoms: A Framework for the Behavioural Phenotyping of Putative Biomarkers"], ["Franca Placenza", 2019, "Reverse Translation of Major Depressive Disorder Symptoms: A Framework for the Behavioural Phenotyping of Putative Biomarkers"], ["Francesco Leri", 2019, "Reverse Translation of Major Depressive Disorder Symptoms: A Framework for the Behavioural Phenotyping of Putative Biomarkers"], ["Stephen Daniels", 2019, "Reverse Translation of Major Depressive Disorder Symptoms: A Framework for the Behavioural Phenotyping of Putative Biomarkers"], ["Alexandra Storace", 2019, "Reverse Translation of Major Depressive Disorder Symptoms: A Framework for the Behavioural Phenotyping of Putative Biomarkers"], ["Stephanie Hassel", 2019, "Reverse Translation of Major Depressive Disorder Symptoms: A Framework for the Behavioural Phenotyping of Putative Biomarkers"], ["Thomas Horman", 2019, "Reverse Translation of Major Depressive Disorder Symptoms: A Framework for the Behavioural Phenotyping of Putative Biomarkers"], ["Pierre Blier", 2019, "Reverse Translation of Major Depressive Disorder Symptoms: A Framework for the Behavioural Phenotyping of Putative Biomarkers"], ["Brett Melanson", 2019, "Reverse Translation of Major Depressive Disorder Symptoms: A Framework for the Behavioural Phenotyping of Putative Biomarkers"], ["Janice T Pong", 2019, "Collaborating with individuals with lived experience to adapt CANMAT clinical depression guidelines into a patient treatment guide: The CHOICE\u2010D co\u2010design process"], ["Andrew Kcomt", 2019, "Collaborating with individuals with lived experience to adapt CANMAT clinical depression guidelines into a patient treatment guide: The CHOICE\u2010D co\u2010design process"], ["Trehani M Fonseka", 2019, "Collaborating with individuals with lived experience to adapt CANMAT clinical depression guidelines into a patient treatment guide: The CHOICE\u2010D co\u2010design process"], ["Dominique Bonneville", 2019, "Sleep disturbances in youth at\u2010risk for serious mental illness"], ["Kali Brummitt", 2019, "Sleep disturbances in youth at\u2010risk for serious mental illness"], ["Jean-Francois Theroux", 2019, "Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants"], ["Chelsey Ju", 2019, "Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants"], ["Zahia Aouabed", 2019, "Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants"], ["Gary Gang Chen", 2019, "Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants"], ["Raoul Belzeaux", 2019, "Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants"], ["Qingqin Li", 2019, "Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants"], ["Jonathan Swann", 2019, "Gut microbial metabolites in depression: understanding the biochemical mechanisms"], ["Giorgia Caspani", 2019, "Gut microbial metabolites in depression: understanding the biochemical mechanisms"], ["Hans-Ulrich Wittchen", 2018, "mood and anxiety disorders"], ["Hyewon Helen Lee", 2018, "Early symptom improvement at 10 sessions as a predictor of rTMS treatment outcome in major depression"], ["Olivia R Allega", 2018, "Performance of the biological rhythms interview for assessment in neuropsychiatry: an item response theory and actigraphy analysis"], ["Matthew Skelly", 2018, "Performance of the biological rhythms interview for assessment in neuropsychiatry: an item response theory and actigraphy analysis"], ["Maria Paz Hidalgo", 2018, "Performance of the biological rhythms interview for assessment in neuropsychiatry: an item response theory and actigraphy analysis"], ["Xiamin Leng", 2018, "Performance of the biological rhythms interview for assessment in neuropsychiatry: an item response theory and actigraphy analysis"], ["Anthony Vaccarino", 2018, "Performance of the biological rhythms interview for assessment in neuropsychiatry: an item response theory and actigraphy analysis"], ["Mariana Lanzini", 2018, "Performance of the biological rhythms interview for assessment in neuropsychiatry: an item response theory and actigraphy analysis"], ["Venkat Bhat", 2017, "Distinct Network Structure of Depression Symptoms Among Responders and Non-Responders to Antidepressants and Placebo"], ["Jennifer Larsen", 2017, "Distinct Network Structure of Depression Symptoms Among Responders and Non-Responders to Antidepressants and Placebo"], ["Jane Foster", 2017, "Distinct Network Structure of Depression Symptoms Among Responders and Non-Responders to Antidepressants and Placebo"], ["Aleksandra Lalovic", 2017, "Sensing depression: Using smartphone sensors to predict changes in depression severity"], ["Michael Merrill", 2017, "Sensing depression: Using smartphone sensors to predict changes in depression severity"], ["Mark Matthews", 2017, "Sensing depression: Using smartphone sensors to predict changes in depression severity"], ["Tanzeem Choudhury", 2017, "Sensing depression: Using smartphone sensors to predict changes in depression severity"], ["Hane Aung", 2017, "Sensing depression: Using smartphone sensors to predict changes in depression severity"], ["Ellen Frank", 2017, "Sensing depression: Using smartphone sensors to predict changes in depression severity"], ["David Kupfer", 2017, "Sensing depression: Using smartphone sensors to predict changes in depression severity"], ["Claudio Soares", 2017, "Sensing depression: Using smartphone sensors to predict changes in depression severity"], ["Victoria Marshe", 2017, "INVESTIGATING ASSOCIATIONS BETWEEN IL-1BETA, IL-2, IL-6, TSPO AND BDNF VARIANTS AND RESPONSE TO DULOXETINE OR PLACEBO TREATMENT IN PATIENTS WITH MAJOR DEPRESSION"], ["Daniel Mueller", 2017, "INVESTIGATING ASSOCIATIONS BETWEEN IL-1BETA, IL-2, IL-6, TSPO AND BDNF VARIANTS AND RESPONSE TO DULOXETINE OR PLACEBO TREATMENT IN PATIENTS WITH MAJOR DEPRESSION"], ["Natalie Freeman", 2017, "INVESTIGATING ASSOCIATIONS BETWEEN IL-1BETA, IL-2, IL-6, TSPO AND BDNF VARIANTS AND RESPONSE TO DULOXETINE OR PLACEBO TREATMENT IN PATIENTS WITH MAJOR DEPRESSION"], ["Arun K Tiwari", 2017, "INVESTIGATING ASSOCIATIONS BETWEEN IL-1BETA, IL-2, IL-6, TSPO AND BDNF VARIANTS AND RESPONSE TO DULOXETINE OR PLACEBO TREATMENT IN PATIENTS WITH MAJOR DEPRESSION"], ["Trehani Fonseka", 2017, "GENOME-WIDE ASSOCIATION STUDY IN DULOXETINE AND PLACEBO RESPONSE"], ["Nicole E Edgar", 2017, "Brexpiprazole in the treatment of major depressive disorder"], ["Maryam I Al Shirawi", 2017, "Brexpiprazole in the treatment of major depressive disorder"], ["Kate Leslie Harkness", 2017, "Childhood maltreatment and markers of neuroinflammation predict response to anti-depressant treatment in adults with major depressive disorder"], ["Benicio Frey", 2017, "Childhood maltreatment and markers of neuroinflammation predict response to anti-depressant treatment in adults with major depressive disorder"], ["Madeline Li", 2017, "Childhood maltreatment and markers of neuroinflammation predict response to anti-depressant treatment in adults with major depressive disorder"], ["Moyez Dharsee", 2017, "Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression"], ["Kenneth R Evans", 2017, "Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression"], ["Mario Liotti", 2017, "Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression"], ["Daniel Blumberger", 2017, "Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression"], ["Prabhjot Dhami", 2017, "Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression"], ["Matthew Frehlich", 2017, "Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression"], ["Rae Price", 2017, "Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression"], ["Esther Alonso", 2017, "Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression"], ["Carola Rong", 2017, "The Efficacy of Psychostimulants in Major Depressive Episodes"], ["Evyn M Peters", 2017, "The Efficacy of Psychostimulants in Major Depressive Episodes"], ["Joshua D Rosenblat", 2017, "The Efficacy of Psychostimulants in Major Depressive Episodes"], ["Jeanette M Jerrell", 2017, "The Efficacy of Psychostimulants in Major Depressive Episodes"], ["Aileen J Zhou", 2017, "The efficacy of psychostimulants in major depressive episodes: a systematic review and meta-analysis"], ["Yena Lee", 2017, "The efficacy of psychostimulants in major depressive episodes: a systematic review and meta-analysis"], ["Roger S McIntyre", 2017, "The efficacy of psychostimulants in major depressive episodes: a systematic review and meta-analysis"], ["Marcelo Berlim", 2017, "Investigation of miR-1202, miR-135a, and miR-16 in major depressive disorder and antidepressant response"], ["Eduardo Chachamovich", 2017, "Investigation of miR-1202, miR-135a, and miR-16 in major depressive disorder and antidepressant response"], ["Fabrice Jollant", 2017, "Investigation of miR-1202, miR-135a, and miR-16 in major depressive disorder and antidepressant response"], ["St\u00e9phane Richard-Devantoy", 2017, "Investigation of miR-1202, miR-135a, and miR-16 in major depressive disorder and antidepressant response"], ["Juan Pablo Lopez", 2017, "Investigation of miR-1202, miR-135a, and miR-16 in major depressive disorder and antidepressant response"], ["Roisin Byrne", 2017, "Oral ketamine in treatment-resistant depression: a clinical effectiveness case series"], ["Keith T Ho", 2017, "Oral ketamine in treatment-resistant depression: a clinical effectiveness case series"], ["Alipasha Meysamie", 2017, "Crocus sativus L. versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial"], ["Samrand Salimi", 2017, "Crocus sativus L. versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial"], ["Mohsen Afarideh", 2017, "Crocus sativus L. versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial"], ["Shahin Akhondzadeh", 2017, "Crocus sativus L. versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial"], ["Nasrin Matinnia", 2017, "Crocus sativus L. versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial"], ["Leila Jahangard", 2017, "Crocus sativus L. versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial"], ["Nafiseh Velayati", 2017, "Crocus sativus L. versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial"], ["Seyede Morvarid Neishabouri", 2017, "Crocus sativus L. versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial"], ["Ali Ghaleiha", 2017, "Crocus sativus L. versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial"], ["Mohammad Haghighi", 2017, "Crocus sativus L. versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial"], ["Alireza Ghajar", 2017, "Crocus sativus L. versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial"], ["Marco Leyton", 2017, "Neuroimaging tests for clinical psychiatry: Are we there yet?"], ["Poonam Jha", 2017, "Concise guide to child and adolescent psychiatry"], ["Mina K Dulcan", 2017, "Concise guide to child and adolescent psychiatry"], ["Rachel R Ballard", 2017, "Concise guide to child and adolescent psychiatry"], ["Julie M Sadhu", 2017, "Concise guide to child and adolescent psychiatry"], ["Harriet Feilotter", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Ming-Hu Han", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Christophe Gerald", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Naguib Mechawar", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Stacy M Ku", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Katherine J Aitchison", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Eric J Nestler", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Gayle M Wittenberg", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Hannah M Cates", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Rixing Lin", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Benoit Labonte", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Elizabeth A Heller", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Steven C Strother", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Cristiana Cruceanu", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Cathryn M Lewis", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Kathrin Tyryshkin", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Vincent Vialou", 2017, "MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes"], ["Katherine Wynne-Edwards", 2017, "751. The Role of Childhood Maltreatment in Depression: Overview of the Literature and Insights from the CAN-BIND Program"], ["Kate Harkness", 2017, "751. The Role of Childhood Maltreatment in Depression: Overview of the Literature and Insights from the CAN-BIND Program"], ["Laura Fiori", 2017, "753. The Influence of Early Life Trauma on Epigenetic Markers in a CAN-BIND Sample of Responders and Non-Responders to Escitalopram"], ["Sarah K Peters", 2017, "608. Baseline Resting-State fMRI Biomarkers of Depression Response to DLPFC-rTMS: Different Patterns of Functional Connectivity Predict Response to 10 Hz rTMS and Intermittant TBS"], ["Zafiris Daskalakis", 2017, "608. Baseline Resting-State fMRI Biomarkers of Depression Response to DLPFC-rTMS: Different Patterns of Functional Connectivity Predict Response to 10 Hz rTMS and Intermittant TBS"], ["Stephen Strother", 2017, "754. Inflammatory Markers as Mediators of the Association between Early Life Adversity and Hippocampal Volume in Adult Patients with depression: Findings from Phase 1 of the \u2026"], ["Stephen Arnott", 2017, "754. Inflammatory Markers as Mediators of the Association between Early Life Adversity and Hippocampal Volume in Adult Patients with depression: Findings from Phase 1 of the \u2026"], ["Geoffrey Hall", 2017, "754. Inflammatory Markers as Mediators of the Association between Early Life Adversity and Hippocampal Volume in Adult Patients with depression: Findings from Phase 1 of the \u2026"], ["Gesine Alders", 2017, "754. Inflammatory Markers as Mediators of the Association between Early Life Adversity and Hippocampal Volume in Adult Patients with depression: Findings from Phase 1 of the \u2026"], ["SH Kennedy", 2017, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder (vol 61, pg 540, 2016)"], ["RS McIntyre", 2017, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder (vol 61, pg 540, 2016)"], ["RW Lam", 2017, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder (vol 61, pg 540, 2016)"], ["Hanna O Woldeyohannes", 2017, "A pilot, open\u2010label, 8\u2010week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression"], ["Rodrigo B Mansur", 2017, "A pilot, open\u2010label, 8\u2010week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression"], ["Elisa Brietzke", 2017, "A pilot, open\u2010label, 8\u2010week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression"], ["Joanna K Soczynska", 2017, "A pilot, open\u2010label, 8\u2010week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression"], ["Valerie H Taylor", 2017, "A pilot, open\u2010label, 8\u2010week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression"], ["Mohammad Alsuwaidan", 2017, "A pilot, open\u2010label, 8\u2010week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression"], ["Roumen V Milev", 2017, "Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression"], ["Arun V Ravindran", 2017, "Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression"], ["Gerald P McKinley", 2017, "Is tetraethyl lead poison affecting contemporary indigenous suicides in Ontario, Canada?"], ["Trehani Mary Fonseka", 2017, "Is tetraethyl lead poison affecting contemporary indigenous suicides in Ontario, Canada?"], ["Emily VonderPorten", 2017, "A SYSTEMATIC REVIEW OF TREATMENTS FOR DEPRESSION IN PERIMENOPAUSAL AND POSTMENOPAUSAL WOMEN"], ["Miki Peer", 2017, "A SYSTEMATIC REVIEW OF TREATMENTS FOR DEPRESSION IN PERIMENOPAUSAL AND POSTMENOPAUSAL WOMEN"], ["Lana Mamisashvili", 2017, "A SYSTEMATIC REVIEW OF TREATMENTS FOR DEPRESSION IN PERIMENOPAUSAL AND POSTMENOPAUSAL WOMEN"], ["Gail Robinson", 2017, "A SYSTEMATIC REVIEW OF TREATMENTS FOR DEPRESSION IN PERIMENOPAUSAL AND POSTMENOPAUSAL WOMEN"], ["Sophie Grigoriadis", 2017, "A SYSTEMATIC REVIEW OF TREATMENTS FOR DEPRESSION IN PERIMENOPAUSAL AND POSTMENOPAUSAL WOMEN"], ["Arsalan Mir-Moghtadaei", 2017, "Scalp-based heuristics for locating the nodes of the salience network for use in neurostimulation"], ["RH Lam", 2017, "Scalp-based heuristics for locating the nodes of the salience network for use in neurostimulation"], ["Katie Dunlop", 2017, "Scalp-based heuristics for locating the nodes of the salience network for use in neurostimulation"], ["ZJ Daskalakis", 2017, "Response to 10 Hz rTMS or iTBS to the left DLPFC is associated with increased cortico-striatal connectivity."], ["J Downar", 2017, "Response to 10 Hz rTMS or iTBS to the left DLPFC is associated with increased cortico-striatal connectivity."], ["F Mansouri", 2017, "Response to 10 Hz rTMS or iTBS to the left DLPFC is associated with increased cortico-striatal connectivity."], ["SK Peters", 2017, "Response to 10 Hz rTMS or iTBS to the left DLPFC is associated with increased cortico-striatal connectivity."], ["K Dunlop", 2017, "Response to 10 Hz rTMS or iTBS to the left DLPFC is associated with increased cortico-striatal connectivity."], ["P Giacobbe", 2017, "Response to 10 Hz rTMS or iTBS to the left DLPFC is associated with increased cortico-striatal connectivity."], ["DM Blumberger", 2017, "Response to 10 Hz rTMS or iTBS to the left DLPFC is associated with increased cortico-striatal connectivity."], ["F Vila-Rodriguez", 2017, "Response to 10 Hz rTMS or iTBS to the left DLPFC is associated with increased cortico-striatal connectivity."], ["F Vila-Rodriquez", 2017, "Cortico-cortical and cortico-striatal resting-state functional connectivity differentially predicts response to 10 Hz rTMS and intermittent TBS to the DLPFC"], ["Barbara J Sahakian", 2017, "A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major \u2026"], ["Michael W Best", 2017, "A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major \u2026"], ["Laura Ashley Gallaugher", 2017, "A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major \u2026"], ["Danielle S Cha", 2017, "A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major \u2026"], ["Jane P Lui", 2017, "A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major \u2026"], ["Gary Lewis", 2017, "A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major \u2026"], ["Christopher R Bowie", 2017, "A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major \u2026"], ["Gary Remington", 2017, "Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression"], ["Amanda K Ceniti", 2017, "Neurocognitive predictors of response in treatment resistant depression to subcallosal cingulate gyrus deep brain stimulation"], ["Anna Cyriac", 2017, "Neurocognitive predictors of response in treatment resistant depression to subcallosal cingulate gyrus deep brain stimulation"], ["Heather E McNeely", 2017, "Neurocognitive predictors of response in treatment resistant depression to subcallosal cingulate gyrus deep brain stimulation"], ["Shane J McInerney", 2017, "Neurocognitive predictors of response in treatment resistant depression to subcallosal cingulate gyrus deep brain stimulation"], ["Joseph Geraci", 2017, "Neurocognitive predictors of response in treatment resistant depression to subcallosal cingulate gyrus deep brain stimulation"], ["Lauren E Mak", 2017, "The default mode network in healthy individuals: a systematic review and meta-analysis"], ["Michael Rosenbluth", 2017, "Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines: Key Considerations"], ["Paula Ravitz", 2017, "Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines: Key Considerations"], ["Lena Quilty", 2017, "Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines: Key Considerations"], ["Barbara Pavlova", 2017, "Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines: Key Considerations"], ["Vytas Velyvis", 2017, "Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines: Key Considerations"], ["Benjamin Hsu", 2017, "Sirukumab: a potential treatment for mood disorders?"], ["Giacomo Salvadore", 2017, "Sirukumab: a potential treatment for mood disorders?"], ["Anthony L Vaccarino", 2016, "Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first \u2026"], ["Harriet E Feilotter", 2016, "Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first \u2026"], ["Lena C Quilty", 2016, "Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first \u2026"], ["Colleen Brenner", 2016, "Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first \u2026"], ["Franca M Placenza", 2016, "Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first \u2026"], ["Tim V Salomons", 2016, "Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first \u2026"], ["Ana C Andreazza", 2016, "Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first \u2026"], ["S Rizvi", 2016, "The prominence of anhedonia in treatment-resistant depression and links to dopamine receptor binding"], ["Antonio Strafella", 2016, "The prominence of anhedonia in treatment-resistant depression and links to dopamine receptor binding"], ["Pablo Rusjan", 2016, "The prominence of anhedonia in treatment-resistant depression and links to dopamine receptor binding"], ["B Sproule", 2016, "The prominence of anhedonia in treatment-resistant depression and links to dopamine receptor binding"], ["Maj Vinberg", 2016, "Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project"], ["Ida K Wium-Andersen", 2016, "Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project"], ["Roman M Dale", 2016, "Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project"], ["Nadia A Maruschak", 2016, "Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project"], ["Holly X Xiao", 2016, "Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project"], ["David J Muzina", 2016, "Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project"], ["Andre F Carvalho", 2016, "Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project"], ["Mohammad T Alsuwaidan", 2016, "Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project"], ["David V Sheehan", 2016, "The Depression Inventory Development Workgroup: a collaborative, empirically driven initiative to develop a new assessment tool for major depressive disorder"], ["Terrence Sills", 2016, "The Depression Inventory Development Workgroup: a collaborative, empirically driven initiative to develop a new assessment tool for major depressive disorder"], ["Janet BW Williams", 2016, "The Depression Inventory Development Workgroup: a collaborative, empirically driven initiative to develop a new assessment tool for major depressive disorder"], ["Nina Engelhardt", 2016, "The Depression Inventory Development Workgroup: a collaborative, empirically driven initiative to develop a new assessment tool for major depressive disorder"], ["John H Greist", 2016, "The Depression Inventory Development Workgroup: a collaborative, empirically driven initiative to develop a new assessment tool for major depressive disorder"], ["Amir H Kalali", 2016, "The Depression Inventory Development Workgroup: a collaborative, empirically driven initiative to develop a new assessment tool for major depressive disorder"], ["Kenneth A Kobak", 2016, "The Depression Inventory Development Workgroup: a collaborative, empirically driven initiative to develop a new assessment tool for major depressive disorder"], ["Guy Faulkner", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 5. Complementary and \u2026"], ["Diane McIntosh", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 5. Complementary and \u2026"], ["Lakshmi N Yatham", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 5. Complementary and \u2026"], ["Lynda G Balneaves", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 5. Complementary and \u2026"], ["Abigail Ortiz", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 5. Complementary and \u2026"], ["Lakshmi Ravindran", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 5. Complementary and \u2026"], ["Rachel L Morehouse", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 5. Complementary and \u2026"], ["CANMAT Depression Work Group", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 5. Complementary and \u2026"], ["Meir Steiner", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations \u2026"], ["Natalia Jaworska", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations \u2026"], ["Ryan J Van Lieshout", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations \u2026"], ["Theo Kolivakis", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. Disease burden and \u2026"], ["Erin E Michalak", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. Disease burden and \u2026"], ["Wei-Yi Song", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. Disease burden and \u2026"], ["Jitender Sareen", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. Disease burden and \u2026"], ["Murray W Enns", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. Disease burden and \u2026"], ["Mandana Modirrousta", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. Neurostimulation \u2026"], ["Simon Patry", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. Neurostimulation \u2026"], ["Mehrul Hasnain", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological \u2026"], ["Norma L Pearson", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological \u2026"], ["Anthony J Levitt", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological \u2026"], ["S Val\u00e9rie Tourjman", 2016, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological \u2026"], ["Lakshmi Yatham", 2016, "Admixture analysis of age at onset in first episode bipolar disorder"], ["Vincenzo De Luca", 2016, "Admixture analysis of age at onset in first episode bipolar disorder"], ["Behdin Nowrouzi", 2016, "Admixture analysis of age at onset in first episode bipolar disorder"], ["Kahlood Syeda", 2016, "Binge eating in adults with mood disorders: Results from the International Mood Disorders Collaborative Project"], ["Jeanette Jerrell", 2016, "Binge eating in adults with mood disorders: Results from the International Mood Disorders Collaborative Project"], ["Laura A Gallaugher", 2016, "Binge eating in adults with mood disorders: Results from the International Mood Disorders Collaborative Project"], ["Lee Bartel", 2016, "A pilot study investigating the effects of rhythmic sensory stimulation with low-frequency sounds on depression"], ["Thenille Braun Janzen", 2016, "A pilot study investigating the effects of rhythmic sensory stimulation with low-frequency sounds on depression"], ["Beth A Sproule", 2016, "Assessing anhedonia in depression: potentials and pitfalls"], ["Diego A Pizzagalli", 2016, "Assessing anhedonia in depression: potentials and pitfalls"], ["Beth Sproule", 2016, "Neurobiological Correlates of Anhedonia in Treatment Resistant Depression"], ["Andre Carvalho", 2016, "The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive \u2026"], ["Roman S Dale", 2016, "The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive \u2026"], ["Terence A Ketter", 2016, "Ketamine: stimulating antidepressant treatment?"], ["Michael J Ostacher", 2016, "Ketamine: stimulating antidepressant treatment?"], ["Rupert McShane", 2016, "Ketamine: stimulating antidepressant treatment?"], ["Andrea Cipriani", 2016, "Ketamine: stimulating antidepressant treatment?"], ["Frederick Cassidy", 2016, "Ketamine: stimulating antidepressant treatment?"], ["Alex J Mitchell", 2016, "Ketamine: stimulating antidepressant treatment?"], ["Yulisha Byrow", 2016, "Ketamine: stimulating antidepressant treatment?"], ["Mark A Frye", 2016, "Ketamine: stimulating antidepressant treatment?"], ["Gin S Malhi", 2016, "Ketamine: stimulating antidepressant treatment?"], ["Michael E Thase", 2016, "Ketamine: stimulating antidepressant treatment?"], ["Michael Gitlin", 2016, "Ketamine: stimulating antidepressant treatment?"], ["Mauricio Tohen", 2016, "Ketamine: stimulating antidepressant treatment?"], ["Koen Demyttenaere", 2016, "Ketamine: stimulating antidepressant treatment?"], ["Jeffrey R Vittengl", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Roland Mergl", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Daniel David", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Pim Cuijpers", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Sona Dimidjian", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Jos Twisk", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Ioana Cristea", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Steven D Hollon", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Robin B Jarrett", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Boadie W Dunlop", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Zindel V Segal", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Ulrich Hegerl", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Erica Weitz", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["A John Rush", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["David C Mohr", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Mahbobeh Faramarzi", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Farzan Kheirkhah", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Robert J DeRubeis", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Jeanne Miranda", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Anne D Simons", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Juned Siddique", 2016, "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression"], ["Philip Gorwood", 2016, "Cognition and biomarkers in major depressive disorder: endophenotype or epiphenomenon?"], ["Carole Bela\u00efdi", 2016, "Sustained efficacy of agomelatine 10 mg, 25 mg, and 25\u201350 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled \u2026"], ["Alla Avedisova", 2016, "Sustained efficacy of agomelatine 10 mg, 25 mg, and 25\u201350 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled \u2026"], ["Christian de Bodinat", 2016, "Sustained efficacy of agomelatine 10 mg, 25 mg, and 25\u201350 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled \u2026"], ["Fran\u00e7oise Picarel-Blanchot", 2016, "Sustained efficacy of agomelatine 10 mg, 25 mg, and 25\u201350 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled \u2026"], ["Martin A Katzman", 2016, "Functional recovery in major depressive disorder"], ["Jeffrey Habert", 2016, "Functional recovery in major depressive disorder"], ["Oloruntoba J Oluboka", 2016, "Functional recovery in major depressive disorder"], ["Xiao\u2010Yan Wen", 2016, "Zebrafish models of major depressive disorders"], ["James Kennedy", 2015, "Genome-Wide Association Analyses on Clinical Response to Duloxetine and Placebo in Major Depression Implicates a Gene Locus Involved in Nociception to be Associated with \u2026"], ["Arun Tiwari", 2015, "Genome-Wide Association Analyses on Clinical Response to Duloxetine and Placebo in Major Depression Implicates a Gene Locus Involved in Nociception to be Associated with \u2026"], ["Laura Gallaugher", 2015, "Correlates of benzodiazepine use in major depressive disorder: the effect of anhedonia"], ["Erica S Weitz", 2015, "Baseline depression severity as moderator of depression outcomes between cognitive behavioral therapy vs pharmacotherapy: an individual patient data meta-analysis"], ["Annemieke Van Straten", 2015, "Baseline depression severity as moderator of depression outcomes between cognitive behavioral therapy vs pharmacotherapy: an individual patient data meta-analysis"], ["Ioana A Cristea", 2015, "Baseline depression severity as moderator of depression outcomes between cognitive behavioral therapy vs pharmacotherapy: an individual patient data meta-analysis"], ["Marcus JH Huibers", 2015, "Baseline depression severity as moderator of depression outcomes between cognitive behavioral therapy vs pharmacotherapy: an individual patient data meta-analysis"], ["Mera S Barr", 2015, "Deep brain stimulation modulates gamma oscillations and theta\u2013gamma coupling in treatment resistant depression"], ["Yinming Sun", 2015, "Deep brain stimulation modulates gamma oscillations and theta\u2013gamma coupling in treatment resistant depression"], ["Chris W Tang", 2015, "Deep brain stimulation modulates gamma oscillations and theta\u2013gamma coupling in treatment resistant depression"], ["Tarek Rajji", 2015, "Deep brain stimulation modulates gamma oscillations and theta\u2013gamma coupling in treatment resistant depression"], ["Paul B Fitzgerald", 2015, "Deep brain stimulation modulates gamma oscillations and theta\u2013gamma coupling in treatment resistant depression"], ["R Michael Bagby", 2015, "Development and validation of the Dimensional Anhedonia Rating Scale (DARS) in a community sample and individuals with major depression"], ["Pauline Gaprielian", 2015, "MRI-guided dmPFC-rTMS as a treatment for treatment-resistant major depressive disorder"], ["Jonathan O Dostrovsky", 2015, "Paired pulse depression in the subcallosal cingulate region of depression patients"], ["William D Hutchison", 2015, "Paired pulse depression in the subcallosal cingulate region of depression patients"], ["Ido Strauss", 2015, "Paired pulse depression in the subcallosal cingulate region of depression patients"], ["Ian A Prescott", 2015, "Paired pulse depression in the subcallosal cingulate region of depression patients"], ["Pauline Zhang", 2015, "Paired pulse depression in the subcallosal cingulate region of depression patients"], ["Luka R Srejic", 2015, "Paired pulse depression in the subcallosal cingulate region of depression patients"], ["M Li", 2015, "The role of metabolic parameters in influencing circulating cytokine levels in depressed and euthymic individuals with bipolar I/II disorder"], ["R McIntyre", 2015, "The role of metabolic parameters in influencing circulating cytokine levels in depressed and euthymic individuals with bipolar I/II disorder"], ["J Soczynska", 2015, "The role of metabolic parameters in influencing circulating cytokine levels in depressed and euthymic individuals with bipolar I/II disorder"], ["M McAndrews", 2015, "The role of metabolic parameters in influencing circulating cytokine levels in depressed and euthymic individuals with bipolar I/II disorder"], ["Carolyn S Dewa", 2015, "Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder"], ["Helen Mayberg", 2015, "Neurocognitive Predictors of Response in Treatment Resistant Depression (TRD) with Deep Brain Stimulation (DBS) Therapy"], ["H McNeely", 2015, "Neurocognitive Predictors of Response in Treatment Resistant Depression (TRD) with Deep Brain Stimulation (DBS) Therapy"], ["Nir Lipsman", 2015, "Vagus nerve stimulation and deep brain stimulation: implantable device-related neurostimulation for treatment-resistant mood disorders"], ["Andres Lozano", 2015, "Vagus nerve stimulation and deep brain stimulation: implantable device-related neurostimulation for treatment-resistant mood disorders"], ["Laura L Schultze", 2015, "Resting-state functional connectivity to subgenual cingulate cortex differentially predicts treatment response for 10 Hz versus intermittent theta-burst rTMS in major depression"], ["Saba Shahab", 2015, "Dorsomedial prefrontal rTMS for major depression: safety, tolerability, and effectiveness for 10 Hz versus iTBS 185 in consecutive cases"], ["Nathan Bakker", 2015, "Dorsomedial prefrontal rTMS for major depression: safety, tolerability, and effectiveness for 10 Hz versus iTBS 185 in consecutive cases"], ["Vanessa F Goncalves", 2015, "The role of genetic variation across IL-1\u03b2, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain"], ["Jeffrey A Lieberman", 2015, "The role of genetic variation across IL-1\u03b2, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain"], ["Herbert Y Meltzer", 2015, "The role of genetic variation across IL-1\u03b2, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain"], ["J Twisk", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["RB Jarrett", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["U Hegerl", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["BW Dunlop", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["SD Hollon", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["M Faramarzi", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["J Siddique", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["P Cuijpers", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["E Weitz", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["ZV Segal", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["AJ Rush", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["JR Vittengl", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["J Miranda", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["DC Mohr", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["RJ DeRubeis", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["R Mergl", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["F Kheirkhah", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["S Dimidjian", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["D David", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["SJ Kennedy", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["A van Straten", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["AD Simmons", 2015, "Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis"], ["Norman A Cohen", 2015, "Falling Down"], ["Scott Kennedy", 2015, "Falling Down"], ["Etienne Grima", 2015, "Depression and employment status in primary and tertiary care settings"], ["Mary Tan", 2015, "Depression and employment status in primary and tertiary care settings"], ["Peter Lin", 2015, "Depression and employment status in primary and tertiary care settings"], ["Joanna Z Soczynska", 2015, "The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project"], ["Andr\u00e9 F Carvalho", 2015, "The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project"]]}